

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 7/22, 7/56, 7/64, 9/00, A61K 38/12		A1	(11) International Publication Number: WO 96/28467
			(43) International Publication Date: 19 September 1996 (19.09.96)
(21) International Application Number: PCT/EP96/01028		(81) Designated States: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 11 March 1996 (11.03.96)			
(30) Priority Data: FI95A000044 13 March 1995 (13.03.95) IT			
(71) Applicant (for all designated States except US): A. MENARINI INDUSTRIE FARMACEUTICHE RIUNITE S.R.L. [IT/IT]; Via Sette Santi, 3, I-50131 Florence (IT).			
(72) Inventors; and		<p>Published</p> <p>With international search report.</p> <p>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p>	
(75) Inventors/Applicants (for US only): ARCAMONE, Federico [IT/IT]; Via 4 Novembre, 26, I-20014 Nerviano (IT). MAGGI, Carlo, Alberto [IT/IT]; Via Michelazzi, 43, I-50100 Florence (IT). QUARTARA, Laura [IT/IT]; Viale Ossimo, 385, I-52037 Sansepolcro (IT). GIANNOTTI, Danilo [IT/IT]; Via Roma, 128, I-55011 Altopascio (IT).			
(74) Agent: GERVASI, Gemma; Notarbartolo & Gervasi S.r.l., Viale Bianca Maria, 33, I-20122 Milan (IT).			

(54) Title: BICYCLIC TACHYKININS ANTAGONISTS, PREPARATION THEREOF AND THEIR USE IN PHARMACEUTICAL COMPOSITION

(57) Abstract

This invention relates to novel compounds of general formula (I) and to pharmaceutical compositions containing them.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

- 1 -

BYCYCLIC TACHYKININS ANTAGONISTS, PREPARATION THEREOF AND
THEIR USE IN PHARMACEUTICAL COMPOSITION

Field of the Invention

5 This invention relates to novel bi-cyclic compounds useful in pharmaceutical compositions as tachykinins antagonists, and to pharmaceutical compositions containing them.

Background of the invention

10 The receptor NK₂ of tachykinins is widely expressed in the peripheral nervous system of Mammalia. One of the several effects caused by the selective stimulation of the receptor NK₂ is the contraction of the smooth muscles. Therefore, antagonists of the receptor NK₂ can be considered agents able to control the hypercontraction of the smooth muscles in any pathological condition in which the release of the tachykinins contributes to the rise of the
15 corrispondent disorder. In particular, the bronchospastic component of asthma, cough, pulmonary irritations and local spasms of the urinary bladder and of the ureter during cystitis, infections and renal colics can be considered conditions in which the administration of receptor NK₂ antagonists can be effective (A.L. Magnan et al. *Neuropeptides*,
20 1993, 24, 199). Compounds which act as antagonists of the tachykinins, and in particular of the neurokinin A, are well-known in Literature. Among them, the cyclic compounds (B. J. Williams et al. *J. Med. Chem.*, 1993, 36, 2) are of particular interest. Lipophily has been defined as an ssential requirement in order to hav an intensive antagonist
25 activity to th receptor NK₂ of th tachykinins of a series of cyclic ps udop ptides (L. Quartara et al. *J. Med. Chem.*, 1994, 27) and


- 2 -

particularly in case of bicyclic hexapeptides. WO/ 93/21227). Surprisingly it has been now found that products structurally similar to those described above, but in which, however, at least one hydrophilic group is present, not only keep their high affinity *in vitro*, but also show an increase in the pharmacological activity *in vivo* if compared to the correspondent compounds which do not contain any hydrophilic group.

This is even more surprising if it is taken into account that monocyclic peptides having antagonist properties which are similar to those of the tachykinins do not show any increase in the pharmacological activity when hydrophilic groups are introduced onto the structure of the cycle [Int. J. Peptide Protein Res. (1984), 44:2, 105-111].

Summary

This invention relates to novel compounds of the general formula (I):



wherein:

$\text{X}_1, \text{X}_2, \text{X}_3, \text{X}_4, \text{X}_5$, and X_6 , same or different from one another, represent a -NR'CO- or a -CONR'- group, wherein R' is H or C_{1-3} alkyl;

- 3 -

Y represents a group selected from -NRCO-, -CONR-, or -SS-

wherein R is H or C₁₋₃ alkyl;


at least one of the R₁, R₂, R₃ and R₄ groups, same or different from one another, is hydrophilic and the remaining groups are hydrophobic;

5 m and n, same or different from one another, are each an integer number from 1 to 4;

and to pharmaceutical compositions containing them.

Detailed description of the Invention

The present invention relates to novel compounds having the general
10 formula (I)




wherein

X₁, X₂, X₃, X₄, X₅, X₆; Y, R₁, R₂, R₃, R₄, m and n groups are as defined above;

processes for the preparation thereof and pharmaceutical compositions containing them.

The formula (I) as reported above is considered the one giving the
15 best representation of the real spatial structure of the bicyclic peptide according to the invention. However also the following Formula (Ia) (which chemically speaking is identical to Formula (I)) is given

in order to simplify the understanding of the compounds described hereinafter and in the Examples with their chemical name in particular in so far as the groups X_{1-6} and Y are concerned.



The groups X_{1-6} and Y are in fact defined according to the aminoacid-sequence from the formal N- to the C-terminus of the peptide as they are represented in the linear structure, therefore reading Formula (Ia) no problem arises in the understanding of the linear structure as reported in the Examples.

As it can be seen, the compounds of formula (I) as described above present chiral centers: it is understood that this invention relates also to the several enantiomers.

More particularly the hydrophobic groups can be separately selected from the following:

a) groups C_nH_{2n+1} wherein $n = 0, 1-4$

b) linear- or branched alkyl groups corresponding to $C_nH_{2n}-U-W$ wherein $n = 1-4$; $U = O, COO, CONH, S$ and $W = \text{alkyl-, aryl or alkylaryl-group}$ containing from 1 to 15 carbon atoms

c) $(CH_2)_n - C_6H_3 - A - B$ wherein $n = 0, 1-3$; A and B, placed in any of the ortho, meta or para positions, same or different from one another, represent H, halogen, OR, NHR, NR_2 , CH_3 , SR wherein R is an alkyl-, aryl- or alkylaryl-group with less than 10 C atoms

d) $(CH_2)_n - C_6H_{10} - R'$ wherein $n = 0, 1-3$ and $R' = H, C_{1-3} \text{ alkyl}$

- 5 -

e) $(\text{CH}_2)_n$ -heterocycle, wherein $n = 0, 1-3$ and for heterocycle it is meant: imidazolyl-2-yl, indolyl-3-yl, furanyl-3-yl, pyridyl-3-yl, imidazolyl-3-yl

f) a $-(\text{CH}_2)_s-$ group, wherein $s = 3, 4$, eventually OH-substituted or
5 condensed with an aromatic group, which cyclizes with one of the two adjacent X_{1-6} groups in order to produce the side chain of proline, hydroxyproline, octahydroindol-2-carboxylic acid, tetrahydroisoquinolinic acid

g) the side chain of a natural hydrophobic amino acid

10 h) the side chain of a natural hydrophilic amino acid, suitably substituted in order to render it hydrophobic

i) the side chain of non-natural hydrophobic amino acids selected from the group consisting of: norleucine, norvaline, alloisoleucine, cyclohexylglycine (Chg), α -amino-n-butyric acid (Aba),

15 cyclohexylalanine (Cha), aminophenylbutyric acid (Pba), phenylalanines mono- and di- substituted in the ortho, meta and para positions of the benzene ring with one or more of the following groups: C_{1-10} alkyl, C_{1-10} alkoxy, halogen, β -2-thienylalanine, β -3-thienylalanine, β -2-furanylalanine, β -3-furanylalanine, β -2-piridylalanine, β -3-piridylalanine, β -4-piridylalanine, β -(1-naphtyl)alanine, β -(2-naphtyl)alanine, O-alkylated serine- threonine- tyrosine-derivatives, S-alkyl cysteine, S-alkyl homocysteine, N-alkyl lysine, N-alkyl ornithine, N-alkyl 2,3 diaminopropionic acid.

25 More particularly, the side chain of a hydrophobic amino acid according to paragraph (g) is the side chain of an amino acid selected from the group consisting of: glycine, alanine, valine, isoleucin, methionine, phenylalanine, tyrosine, tryptophan, proline, histidin,

- 6 -

asparagine, glutamine.

The side chain of a hydrophilic amino acid, suitably substituted in order to render it hydrophobic according to paragraph (h) is the chain of an amino acid selected from the group consisting of: serine,
5 threonine, cysteine, aspartic acid, glutamic acid, t-carboxyglutamic acid, arginine, ornithine, lysine.

Preferably, the hydrophilic groups are selected from L-Q group, wherein L is a chemical bond or a linear or branched C₁₋₆-alkyl residue and Q is a hydrophilic group. Preferably Q is selected from
10 the group consisting of: guanidine, amine, M, OM, -CO-NH-M, -NH-CO-M, an aromatic group which has been mono-, di- or tri-substituted in ortho, meta, para positions with M or OM groups, wherein M is a hydrophilic group.

With the term "hydrophilic group", for Q and M, it is preferably
15 meant:

- i) eventually substituted mono-, di-, tri-glycosidic residues;
- ii) C₁₋₆ linear or cyclic alkyl chains comprising one or more polar groups;
- iii) hydroxyl, amine, guanidine, carboxyl, sulfate, phosphonate,
20 phosphate;
- iv) residues bearing substituted hydrophilic groups which in biologic environment are hydrolysed, re-establishing the hydrophilic function.

As far as the definition according to paragraph (i) hereinabove is
25 conc rned, the following structures are pr ferably meant:

hexoses or pentoses of the D or L s ries in α or β configuration, selected from the group wherein: all C atoms bear a free or protected

- 7 -

hydroxylic group; one or more hydroxyls are substituted by: hydrogen, an amino or acylamino group; C_6 of hexoses and C_5 of pentoses are part of a carboxylic group; and wherein the eventually present 2 or 3 glycosidic units are linked by a glycosidic bond of α or β configuration.

Specific examples of glycosidic groups as defined above are: D or L ribose, D or L arabinose, D or L xylose, D or L lyxose, D or L allose, D or L altrose, D or L glucose, D or L mannose, D or L gulose, D or L idose, D or L galactose, D or L talose, D or L allulose, D or L fructose, D or L sorbose, D or L tagatose; 5-deoxy-D or L-arabinose, 2-deoxy-D or L-glucose, 2-deoxy-D or L-galactose, 2-deoxy-D or L-arabinose, 2-deoxy-D or L-ribose, D or L fucose, D or L ramnose; D-glucosamine, D-mannosamine, D-galactosamine, daunosamine, acosamine and N-acylate derivates thereof with lower fatty acids, i.e. having a N-formylic, acetylic, propionilic, butyric residue; glucuronic acid, galacturonic acid, cellobiose, lactose, maltose, D-lactosamine, celotriose, maltotriose and protected derivates thereof.

The definition according to paragraph (ii) hereinabove applies to chains deriving from a polyol-residue, such as tris(hydroxymethyl)methyl, D or L arabitol, D or L erythrol, D or L galactytol, meso-inositol, D or L mannitol, D or L perseitol, D or L ribitol, D or L sorbitol, D or L xylitol; or those deriving from the residue of tartaric acid, glucaric acid, gluconic acid, bycine, quinic acid, mucic acid, glucosaminic acid.

Among the products of formula (I) as above indicated, the products wherein if one or both R_1 and R_4 groups are hydrophilic, both R_2 and R_3 groups are hydrophobic and vicev rsa, are particularly preferred.

- 8 -

Compounds of formula (I) object of the present invention can be synthesized by the various techniques known in Literature, see e.g. M. Bodansky, "Peptide Chemistry", Springer-Verlag, 1988.

For example by means of in solution synthesis of the linear peptidic chain through subsequent coupling of suitably activated N-protected amino acids to an amino acid or to a C-protected peptidic chain, with isolation of the intermediates, subsequent selective de-protection of the C- and N-terminal chains, cyclization in polar organic solvents in diluted solution, hence selective de-protection of the side chains and at last cyclization of the same in polar organic solvents in diluted solution. The hydrophilic residue can be introduced both as protected amino acid derivative during the peptidic chain synthesis and by means of conjugation to the already formed peptide, as widely disclosed in Literature. Similarly a synthesis in solid phase of the peptidic chain from the C-terminal end to the N-terminal one on a insoluble polymeric support, the cyclization in solid phase between the previously de-protected side chains, the subsequent detachment from the polymeric support by means of hydrolysis in anhydrous hydrofluoric acid containing the suitable scavengers or in trifluoroacetic acid containing the suitable scavengers or in aqueous bases and the cyclization of the monocyclic peptide in polar organic solvents in diluted solution, can be used for the preparation. The hydrophilic residue being introduced according to the above disclosed indications. According to a particular preparation method, the desired product can be obtained in solid phase using the 2-chlorotrytil resin (Barlos et al., Int. J. Peptide Protein Res., 37, 513-520, 1991) substituted with a protected amino acid having the Fmoc group at the N-terminal end;

- 9 -

preferably the amino acid directly bond to the resin is the one having the R_1 or R_3 side chain. After the other amino acids being introduced in the sequence, the peptide is detached from the resin with diluted acetic acid and a first cyclization is performed between the free C-terminal and N-terminal end by means of the conventional classic synthesis methods. Subsequently, the amino acid side chains are de-protected in position 5 and 6, for example with trifluoroacetic acid, and way is given to the second cyclization.

Other synthetic ways are anyway possible and largely described in Literature as above mentioned.

The compounds of formula (I) as above indicated have revealed to be powerful antagonists of the receptor NK_2 of the tachykinins, and hence may be administered in doses which are not higher than those required for the known products.

They can be therefore indicated for the treatment of arthritis, asthma, inflammations, tumoral growth, gastro-intestinal hypermotility, Huntington's disease, neurites, neuralgia, hemicrania, hypertension, urinary incontinence, urticaria, symptoms from carcinoid disease, flu and colds.

The compounds of formula (I) object of the present invention are suitable for the parenteral, oral, inhalatory and sublingual administration for therapeutical purposes to the superior animals and to the humans, achieving pharmacological effects according to the above described features. For parenteral administrations (endovenous, intramuscular and intradermic) sterile solutions or lyophilized chemical preparations are used. For nasal, inhalatory and sublingual administrations, according to the particular instance,

- 10 -

aqueous solutions, aerosol preparations or capsules are used.

The doses of active principle in the above compositions can be comprised between 0.1 and 10 mg/kg of body weight.

EXAMPLE 1.

5 Preparation of cyclo([Asn(β -D-Glc)-Asp-Trp-Phe-Dap-Leu]cyclo(2 β -5 β)) (SEQ ID No. 1) compound of formula (I) wherein $Y=X_1=X_2=X_3=X_4=X_5=X_6=-CO-NH-$; $R_1=-CH_2-CH(CH_3)_2$; $R_2=-CH_2-C_6H_5$, $R_3=-CH_2$ indolyl-3-yl, $R_4=-CH_2-CO-NH-(\beta$ -D-Glc); $m=n=1$ and the carbon atoms $C_1, C_2, C_3, C_4, C_5, C_6$ have L configuration].

10 a) synthesis of the linear peptide H-Asn[(Ac₄O)- β -D-Glc]-Asp(OtBu)-Trp-Phe-Dap(Boc)-Leu-OH.

1 g of 2-chlor trityl resin (1.6 mmol/g, Novabiochem) is functionalized with Fmoc-Leu-OH (0.6 eqs.) as described by Barlos et al., Int. J. Peptide Protein Res., 1991, 37, 513-520. The substitution
15 degree of the resin is determined by dosing the group Fmoc, and it is equal to 0.364 meq/g. The subsequent 4 amino acids are coupled as free acids using an excess 3 of amino acid and HOBt (4 eqs.) and DCC (3 eqs.) as activators with reaction times of 1 hour. In the following order: Fmoc-Dap(Boc)-OH, Fmoc-Phe-OH, Fmoc-Trp-OH, Fmoc-Asp(OtBu)-OH
20 are added. The last amino acid is coupled as Fmoc-Asn[(Ac₄O)- β -D-Glc]-OPfp (Christiansen-Brans et al., J.Chem.Soc. Perkin Trans. I. 1993, 1461-1471), 2 eqs., with HOBt (2 eqs.) as activator, for 3h.

After the de-protection of the group Fmoc, the detachment from the resin is performed, suspending it in 10 mL of a mixture of AcOH, TFE,
25 DCM (1/1/8, v/v) at room temperature for 0.5 h. Thereafter the solvent is evaporated under vacuum at 30°C, it is again mixed with water and it is lyophilized. Yield in raw product: 405 mg (90 %). Title HPLC: 70

- 11 -

%. FAB-MS: $[M+H]^+ = 1266$; t_R : 14.7 min.

b) Synthesis of the bicyclic product cyclo([Asn((Ac₄O)- β -D-Glc)-Asp-Trp-Phe-Dap-Leu]cyclo(2 β -5 β)) (compound 2).

The linear raw product is cyclized in 1 mM solution in DMF, at 4°C, with 1 eq. of PyBOP and 1.2 eqs. of DIEA for 1 h. The mixture is dried and purified in HPLC obtaining 156 mg of the pure product (yield 39 %). Title HPLC: >99 %. FAB-MS: $[M+H]^+ = 1248$; t_R : 18.4 min.

The monocyclic product is de-protected by solving it in 15 ml of TFA containing water at 10 %. After 0.5 h. the mixture is diluted in water and it is lyophilized. The residue is dissolved in 1 mM solution in DMF, the solution is brought to 0°C and 1 eq. of PyBOP and 1.2 eqs. of DIEA are added. After 5 h, it is dried and purified in HPLC. Yield 45 % (70 mg). Title HPLC > 99 %. FAB-MS: $[M+H]^+ = 1074$; t_R : 13.5 min.

c) Synthesis of the bicyclic product cyclo ([Asn(β -D-Glc)-Asp-Trp-Phe-Dap-Leu]cyclo(2 β -5 β))

70 mg of tetraacetate product are dissolved in anhydrous methanol in 5 mM solution. The solution is brought to -20°C and a 1 mM solution of sodium methylate in methanol is added to achieve pH = 11. After 10' acetic acid is added to achieve neutral pH, high dilution with water and lyophilization follow. Yield 60 %. Title HPLC: 98 %. FAB-MS: $[M+H]^+ = 906$; t_R : 9.3 min.

EXAMPLE 2

Preparation of cyclo([Ser(β -D-Glc)-Asp-Trp-Phe-Dap-Leu]cyclo(2 β -5 β)) (SEQ ID No. 2) [compound of Formula (I) wherein: $Y = X_1 = X_2 = X_3 = X_4 = X_5 = X_6 =$ -CO-NH-; $R_1 = -CH_2-CH(CH_3)_2$; $R_2 = -CH_2-C_6H_5$; $R_3 = -CH_2$ -indolyl-3-yl; $R_4 = -CH_2-O-(\beta$ -D-Glc); $m = n = 1$ and $C_1, C_2, C_3, C_4, C_5, C_6$ carbon atoms have L configuration].

- 12 -

a) synthesis of linear peptide H-Ser[(Bz₄O)-β-D-Glc]-Asp(OtBu)-Trp-Phe-Dap(Boc)-Leu-OH.

The same procedure which has been used for Example 1), paragraph a), is utilized here till the addition of the last amino acid, which is coupled as Fmoc-Ser[(Bz₄O)-β-D-Glc]-OPfp (obtained by the procedure which has been described by Vargas-Berenguel et al., J. Chem. Soc. Perkin Trans. I. 1994, 2615, 2619).

The detachment occurs as described above, in Example 1). Yield in raw product: 450 mg (83 %). Title HPLC: 93 %. FAB-MS: [M+H]⁺ = 1487; t_R: 20.8 min.

b) Synthesis of bicyclic product cyclo([Ser[(Bz₄O)-β-D-Glc]-Asp-Trp-Phe-Dap-Leu]cyclo(2β-5β)).

The linear raw product is cyclized in 1mM solution in DMF, at 4°C, with 1 eq. of PyBOP and 1.2 eqs. of DIEA for 1 h. The mixture is dried and purified in HPLC, obtaining 0.16 g of pure product (yield 35 %). Title HPLC: >99 %. FAB-MS: [M+H]⁺ = 1469; t_R: 25.3 min.

The monocyclic product is de-protected by liquefying it in 10 mL of TFA containing water at 10 %. After 0.5 h the mixture is diluted in water and it is lyophilized. The residue is dissolved in 1mM solution in DMF, the solution is brought to 0°C and 1 eq. of PyBOP and 1.2 eqs. of DIEA are added. After 24 h it is dried and purified in HPLC. Yield 63 mg (45 %). Title HPLC: >99 %. FAB-MS: [M+H]⁺ = 1295; t_R: 21.6 min.

c) Synthesis of bicyclic product cyclo([Ser(β-D-Glc)-Asp-Trp-Phe-Dap-Leu]cyclo(2β-5β)).

20 mg of tetrabenzoylate product are dissolved in anhydrous methanol in 5mM solution. The solution is brought to -20°C and a 1mM solution of sodium methylate in methanol is added to achieve pH = 11. After 1.5

- 13 -

h acetic acid is added to achieve neutral pH, high dilution with water and lyophilization follow. Yield: 6.5 mg (48 %). Title HPLC: > 99 %. FAB-MS: $[M+H]^+ = 878$; t_R : 9.6 min.

By similar procedures, the following compounds have been obtained:

5 EXAMPLE 3

cyclo([Asn(β -D-2-deoxy-2-amino-Glc)-Asp-Trp-Phe-Dap-Leu]cyclo(2 β -5 β)) (SEQ ID No. 3) [compound of Formula I) wherein $R_4 = -CH_2-CO-NH-(\beta$ -D-2-deoxy-2-amino-Glc) and the other substituents are as defined in Example 1].

10 EXAMPLE 4

cyclo ([Asn(β -D-2-deoxy-2-acetamido-Glc)-Asp-Trp-Phe-Dap-Leu]cyclo(2 β -5 β)) (SEQ ID No. 4) [compound of Formula I) wherein $R_4 = -CH_2-CO-NH-(\beta$ -D-2-deoxy-2-acetamido-Glc) and the other substituents are as defined in Example 1].

15 EXAMPLE 5

cyclo ([Nle-Asp-Trp-Phe-Dap-Asn(β -D-2-deoxy-2-acetamido-Glc]cyclo(2 β -5 β)) (SEQ ID No. 5) [compound of Formula I) wherein $R_1 = -CH_2-CO-NH-(\beta$ -D-2-deoxy-2-acetamido-Glc), $R_4 = -(CH_2)_3-CH_3$] and the other substituents are as defined in Example 1].

20 EXAMPLE 6

cyclo([Asn(β -D-ribofuranosyl)-Asp-Trp-Phe-Dap-Leu]cyclo(2 β -5 β)) (SEQ ID No. 6) [compound of Formula I) wherein $R_4 = -CH_2-CO-NH-(\beta$ -D-ribofuranosyl) and the other substituents are as defined in Example 1].

25 EXAMPLE 7

cyclo([Ser(β -D-ribofuranosyl)-Asp-Trp-Phe-Dap-Leu]cyclo(2 β -5 β)) (SEQ ID No. 7) [compound of Formula I) wherein $R_4 = -CH_2-O-(\beta$ -D-

- 14 -

ribofuranosyl), and the other substituents are as defined in Example 1].

EXAMPLE 8

cyclo ([Asn (β -L-arabinofuranosyl)-Asp-Trp-Phe-Dap-Leu]cyclo

- 5 (2 β -5 β)) (SEQ ID No. 8) [compound of Formula I) wherein R_4 = -CH₂-CO-NH-(β -L-arabinofuranosyl) and the other substituents are as defined in Example 1].

EXAMPLE 9

cyclo ([Ser (β -L-arabinofuranosyl)-Asp-Trp-Phe-Dap-Leu]cyclo

- 10 (2 β -5 β)) (SEQ ID No. 9) [compound of Formula I) wherein R_4 = -CH₂-O-(β -L-arabinofuranosyl) and the other substituents are as defined in Example 1].

EXAMPLE 10

cyclo([Asn(β -D-mannopyranosyl)-Asp-Trp-Phe-Dap-Leu]cyclo(2 β -5 β))

- 15 (SEQ ID 10) [compound of Formula I) wherein R_4 = -CH₂-CO-NH-(β -D-mannopyranosyl) and the other substituents are as defined in Example 1].

EXAMPLE 11

cyclo([Ser(β -D-mannopyranosyl)-Asp-Trp-Phe-Dap-Leu]cyclo(2 β -5 β))

- 20 (SEQ ID No. 11) [compound of Formula I) wherein: R_4 = -CH₂-O-(β -D-mannopyranosyl) and the other substituents are as defined in Example 1].

EXAMPLE 12

cyclo ([Asn (β -D-galactopyranosyl)-Asp-Trp-Phe-Dap-Leu]cyclo

- 25 (2 β -5 β)) (SEQ ID No. 12) [compound of Formula I) wherein R_4 = -CH₂-CO-NH-(β -D-galactopyranosyl) and the other substituents are as defined in Example 1].

- 15 -

EXAMPLE 13

cyclo([Ser(β -D-galactopyranosyl)-Asp-Trp-Phe-Dap-Leu]cyclo(2 β -5 β)
(SEQ ID No. 13) [compound of Formula I) wherein $R_4 = -CH_2-O-(\beta$ -D-galactopyranosyl) and the other substituents are as defined in Example
5 1].

EXAMPLE 14

cyclo ([Asn(β -D-glucuronopyranosyl)-Asp-Trp-Phe-Dap-Leu]cyclo
(2 β -5 β)) (SEQ ID No. 14) [compound of Formula I) wherein $R_4 = -CH_2-CO-$
NH-(β -D-glucuronopyranosyl) and the other substituents are as defined
10 in Example 1].

EXAMPLE 15

cyclo([Ser(β -D-glucuronopyranosyl)-Asp-Trp-Phe-Dap-Leu] cyclo
(2 β -5 β)) (SEQ ID No. 15) [compound of Formula I) wherein $R_4 = -CH_2-O-$
(β -D-glucuronopyranosyl) and the other substituents are as defined in
15 Example 1].

EXAMPLE 16

cyclo ([Asn(1-deoxy-sorbitol-1-yl)-Asp-Trp-Phe-Dap-Leu] cyclo
(2 β -5 β)) (SEQ ID 16) [compound of Formula I) wherein $R_4 = -CH_2-CO-NH-$
(1-deoxy-sorbitol-1-yl) and the other substituents are as defined in
20 Example 1].

EXAMPLE 17

cyclo ([Asn[4-O-(α -D-Glc)- β -D-Glc]]-Asp-Trp-Phe-Dap-Leu]cyclo-
(2 β -5 β)) (SEQ ID No. 17) [compound of Formula I) wherein $R_4 = -CH_2-CO-$
NH-[4-O-(α -D-Glc)- β -D-Glc]] and the other substituents are as defined
25 in Example 1].

EXAMPLE 18

cyclo([Asn[4-O-(α -D-galactopyranosyl)- β -D-Glc]-Asp-Trp-Phe-Dap-

- 16 -

Leu]cyclo(2 β -5 β)) (SEQ ID No. 18) [compound of Formula I) wherein R₄ = -CH₂-CO-NH-[4-O(β -D-galactopyranosyl)- β -D-Glc)] and the other substituents are as defined in Example 1].

EXAMPLE 19

5 cyclo ([Asn [0- α -D-Glc-(1-4)-O- α -D-Glc-(1-4)- α -D-Glc]-Asp-Trp-Phe-Dap-Leu] cyclo(2 β -5 β)) (SEQ ID No. 19) [compound of Formula I) wherein: R₄ = -CH₂-CO-NH-[O- α -D-Glc-(1-4)-O- α -D-Glc-(1-4)- α -D-Glc) and the other substituents are as defined in Example 1].

EXAMPLE 20

10 cyclo([Asn(D-2-deoxy-glucopyranos-2-yl)-Asp-Trp-Phe-Dap-Leu]cyclo(2 β -5 β)) (SEQ ID No. 20) [compound of Formula I) wherein R₄ = -CH₂-CO-NH-(D-2-deoxy-glucopyranos-2-yl) and the other substituents are as defined in Example 1].

EXAMPLE 21

15 cyclo ([Dap[D(-)-quinyl]-Asp-Trp-Phe-Dap-Leu]cyclo(2 β -5 β)) (SEQ ID No. 21) [compound of Formula I) wherein: R₄ = -CH₂-NH-[D(-)-quinyl], and the other substituents are as defined in Example 1].

EXAMPLE 22

cyclo ([Dap[D-gluconyl]-Asp-Trp-Phe-Dap-Leu] cyclo(2 β -5 β))
20 (SEQ ID No. 22) [compound of Formula I) wherein: R₄ = -CH₂-NH-(D-gluconyl) and the other substituents are as defined in Example 1].

EXAMPLE 23

cyclo ([Dap[D-glucuryl]-Asp-Trp-Phe-Dap-Leu]cyclo(2 β -5 β))
(SEQ ID No. 23) [compound of Formula I) wherein R₄ = -CH₂-NH-(D-glucuryl) and the other substituents are as defined in Example 1].
25

EXAMPLE 24

cyclo ([Dap(2-sulfo-benzoyl)-Asp-Trp-Phe-Dap-Leu] cyclo (2 β -5 β))

- 17 -

(SEQ ID No. 24) [compound of Formula I) wherein: $R_4 = -CH_2-NH-CO-C_6H_4-SO_3H$ and the other substituents are as defined in Example 1].

EXAMPLE 25

cyclo ([Asn (4-sulfo-phenyl)-Asp-Trp-Phe-Dap-Leu] cyclo (2 β -5 β))

5 (SEQ ID No. 25) [compound of Formula I) wherein $R_4 = CH_2-CO-NH-C_6H_4-SO_3H$ and the other substituents are as defined in Example 1].

EXAMPLE 26

cyclo([Asn(β -L-Glc)-Asp-Trp-Phe-Dap-Leu]cyclo(2 β -5 β)) (SEQ ID No. 26)
[compound of Formula I) wherein $R_4 = -CH_2-CO-NH(\beta$ -L-Glc) and the other
10 substituents are as defined in Example 1].

EXAMPLE 27

cyclo([Asn(β -D-2-deoxy-glucopyranos-2-yl)-Asp-Trp-Phe-Dap-
Leu]cyclo(2 β -5 β)) (SEQ ID No. 27) [compound of formula I) wherein R_4
= $-CH_2-CO-NH-(D$ -2-deoxy-glucopyranos-2-yl) and the other substituents
15 are as defined in Example 1].

EXAMPLE 28

cyclo ([Asn(D-2-deoxy-mannopyranos-2-yl)-Asp-Trp-Phe-Dap-Leu]-
cyclo(2 β -5 β)) (SEQ ID No. 28) [compound of formula I) wherein $R_4 = -$
CH₂-CO-NH-(D-2-deoxy-mannopyranos-2-yl) and the other substituents are
20 as defined in Example 1].

EXAMPLE 29

cyclo ([Asn(D-2-deoxy-galactopyranos-2-yl)-Asp-Trp-Phe-Dap-Leu]-
cyclo(2 β -5 β)) (SEQ ID No. 29) [compound of formula I) wherein $R_4 = -$
CH₂-CO-NH-(D-2-deoxy-galactopyranos-2-yl) and the other substituents
25 are as defined in Example 1].

EXAMPLE 30

cyclo ([Asn(β -D-xylopyranosyl)-Asp-Trp-Phe-Dap-Leu]cyclo(2 β -5 β))

- 18 -

(SEQ ID No. 30) [compound of formula I) wherein $R_4 = -CH_2-CO-NH-(\beta-D$ -xylo-pyranosyl) and the other substituents are as defined in Example 1].

EXAMPLE 31

5 cyclo ([Asn(3-sulfo-propionyl)-Asp-Trp-Phe-Dap-Leu]cyclo-(2 β -5 β))

(SEQ ID 31) [compound of formula I) wherein $R_4 = -CH_2-CO-NH-(3$ -sulfo-propionyl) and the other substituents are as defined in Example 1].

EXAMPLE 32

cyclo ([Dap(Lysyl)-Asp-Trp-Phe-Dap-Leu]cyclo(2 β -5 β)) (SEQ ID No. 32)

10 [compound of formula I) wherein $R_4 = -CH_2-CO-NH-(Lysyl)$ and the other substituents are as defined in Example 1].

EXAMPLE 33

cyclo ([Dap(Arginyl)-Asp-Trp-Phe-Dap-Leu]cyclo(2 β -5 β)) (SEQ ID No. 33)

15 [compound of formula I) wherein $R_4 = -CH_2-CO-NH-(Arginyl)$ and the other substituents are as defined in Example 1].

EXAMPLE 34

cyclo ([Dap(4-O- β -D-galactopyranosyl)-Asp-Trp-Phe-Dap-Leu]cyclo-

20 (2 β -5 β)) (SEQ ID No. 34) [compound of formula I) wherein $R_4 = -CH_2-CO-NH-(4-O-\beta$ -D-galactopyranosyl) and the other substituents are as defined in Example 1].

EXAMPLE 35

cyclo ([Asn(2-deoxy-2-trifluoroacetamido- β -D-Glc)-Asp-Trp-Phe-Dap-Leu]cyclo(2 β -5 β)) (SEQ ID No. 35) [compound of formula I) wherein $R_4 = -CH_2-CO-NH-(2$ -deoxy-2-trifluoroacetamido- β -D-Glc) and the other
25 substituents are as defined in Example 1].

BIOLOGICAL ACTIVITY

The capability of the compounds of the present invention to interact

- 19 -

as agonists or antagonists with the neurokynin A (NKA) receptor has been valued in a in vitro test using the pulmonary artery of a rabbit (RPA) (Rovero et al., Neuropeptides, 1989, 13, 263-270) and their activity was determined as pK_B (antilogarithm of the dissociation constant), as described in Jenkinson et al., TIPS, 12, 53-56, 1991. For example, compound 2 has shown a $pK_B = 8.67$. The capability of the products of the present invention to interact as agonists or antagonists with NKA receptor has been valued in vivo as capability, after intravenous administration, to inhibit the agonist [betaAla⁸] NKA (4-10)-induced contractions of the urinary bladder in the anaesthetized mouse, as described in Maggi et al., J. Pharmacol. Exp. Ther., 1991, 257, 1172. Compound 1, e.g., causes, at dose of 10 nmol/Kg i.v., an inhibitory effect of 50-70 %, as it has been valued at different times. The effect lasts over a period of more than 3 hours.

ABBREVIATIONS:

Asn(β -D-Glc): N⁸-(β -D-glucopiranosyl)-L-asparagineAsn[(Ac₄O)- β -D-Glc]: N⁸-(2,3,4,6-tetra-O-acetyl- β -D-glucopiranosyl)-L-asparagine20 Fmoc-Asn[(Ac₄O)- β -D-Glc]-OPfp: N⁸-(2,3,4,6-tetra-O-acetyl- β -D-glucopiranosyl)N^a-(fluoren-9-ylmethoxycarbonyl)-L-asparagine pentafluorophenyl esthereSer(β -D-Glc): O⁸-(β -D-glucopiranosyl)L-asparagine25 Ser[(Bz₄O)- β -D-Glc]: O⁸-(2,3,4,6-tetra-O-benzoyl- β -D-glucopiranosyl)L-asparaginFmoc-Ser[(Bz₄O)- β -D-Glc]-OPfp: O⁸-(2,3,4,6-tetra-o-benzoyl- β -D-

- 20 -

glucopiranosyl)N^a-(fluoren-9-ylmethoxycarbonyl)-L-serine
pentafluorophenyl ester.

Glc: glucopyranosyl

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

- (A) NAME: A. MENARINI INDUSTRIE FARMACEUTICHE RIUNITE Srl
- (B) STREET: Via Sette Santi, 3
- (C) CITY: Firenze
- (D) STATE: Firenze
- (E) COUNTRY: Italy
- (F) POSTAL CODE (ZIP): 50131
- (G) TELEPHONE: 055-56801
- (H) TELEFAX: 055-5680615

(ii) TITLE OF INVENTION: Bicyclic compounds, preparation thereof
and use in pharmaceutical compositions

(iii) NUMBER OF SEQUENCES: 35

(iv) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)

(vi) PRIOR APPLICATION DATA:

- (A) APPLICATION NUMBER: IT FI 95 A 000044
- (B) FILING DATE: 13-MAR-1995

(vi) CURRENT APPLICATION DATA:

- (A) APPLICATION NUMBER:
- (B) FILING DATE:
- (C) CLASSIFICATION:

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: bicyclic

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 5
- (D) OTHER INFORMATION: Xaa is Dap, i.e. diamino propionic

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1
- (D) OTHER INFORMATION: Asn is Asn(β -D-Glc), wherein Glc is glucopyranosyl

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1 and 6
- (D) OTHER INFORMATION: Asn and Leu are bound together to form a first cyclo

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 2 and 5
- (D) OTHER INFORMATION: Asp and Dap are bound together to form a second cyclo

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

Asn Asp Trp Phe Xaa Leu
1 5

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: bicyclic

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 5
- (D) OTHER INFORMATION: Xaa is Dap, i.e. diamino propionic

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1
- (D) OTHER INFORMATION: Ser is Ser(β -D-Glc), wherein Glc is glucopyranosyl

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1 and 6
- (D) OTHER INFORMATION: Ser and Leu are bound together to form a first cyclo

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 2 and 5
- (D) OTHER INFORMATION: Asp and Dap are bound together to form a second cyclo

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Ser Asp Trp Phe Xaa Leu
1 5

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: bicyclic

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 5
- (D) OTHER INFORMATION: Xaa is Dap, i.e. diamino propionic

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1
- (D) OTHER INFORMATION: Asn is Asn(β -D-2-deoxy-2-amino-Glc), wherein Glc is glucopyranosyl

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1 and 6
- (D) OTHER INFORMATION: Asn and Leu are bound together to form a first cyclo

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 2 and 5
- (D) OTHER INFORMATION: Asp and Dap are bound together to form a second cyclo

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

Asn Asp Trp Phe Xaa Leu
1 5

(2) INFORMATION FOR SEQ ID NO: 4:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: bicyclic

(ii) MOLECULE TYPE: peptide

- (ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 5
(D) OTHER INFORMATION: Xaa is Dap, i.e. diamino propionic

- (ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 1
(D) OTHER INFORMATION: Asn is Asn(β -D-2-deoxy-2-acetamido-Glc), wherein Glc is glucopyranosyl

- (ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 1 and 6
(D) OTHER INFORMATION: Asn and Leu are bound together to form a first cyclo

- (ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 2 and 5
(D) OTHER INFORMATION: Asp and Dap are bound together to form a second cyclo

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

Asn Asp Trp Phe Xaa Leu
1 5

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: bicyclic

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1
- (D) OTHER INFORMATION: Xaa is Nle, i.e. norleucine

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 5
- (D) OTHER INFORMATION: Xaa is Dap, i.e. diamino propionic

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 6
- (D) OTHER INFORMATION: Asn is Asn(β -D-2-deoxy-2-acetamido-Glc), wherein Glc is glucopyranosyl

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1 and 6
- (D) OTHER INFORMATION: Nle and Asn are bound together to form a first cyclo

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 2 and 5
- (D) OTHER INFORMATION: Asp and Dap are bound together to form a second cyclo

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

Xaa Asp Trp Phe Xaa Leu
1 5

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: bicyclic

(1i) MOLECULE TYPE: peptide

(1x) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 5

(D) OTHER INFORMATION: Xaa is Dap, i.e. diamino propionic

(1x) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 1

(D) OTHER INFORMATION: Asn is Asn(β -D-ribofuranosyl)

(1x) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 1 and 6

(D) OTHER INFORMATION: Asn and Leu are bound together to form a first cyclo

(1x) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 2 and 5

(D) OTHER INFORMATION: Asp and Dap are bound together to form a second cyclo

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

Asn Asp Trp Phe Xaa Leu
1 5

(2) INFORMATION FOR SEQ ID NO: 7:

(1) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 6 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: bicyclic

(1i) MOLECULE TYPE: peptide

(1x) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 5

(D) OTHER INFORMATION: Xaa is Dap, i.e. diamino propionic

(1x) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 1

(D) OTHER INFORMATION: Ser is Ser(β -D-ribofuranosyl)

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1 and 6
- (D) OTHER INFORMATION: Ser and Leu are bound together to form a first cyclo

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 2 and 5
- (D) OTHER INFORMATION: Asp and Dap are bound together to form a second cyclo

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

Ser Asp Trp Phe Xaa Leu
1 5

(2) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: bicyclic

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 5
- (D) OTHER INFORMATION: Xaa is Dap, i.e. diamino propionic

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1
- (D) OTHER INFORMATION: Asn is Asn(β -L-arabinofuranosyl)

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1 and 6
- (D) OTHER INFORMATION: Asn and Leu are bound together to form a first cyclo

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 2 and 5
- (D) OTHER INFORMATION: Asp and Dap are bound together to form a second cyclo

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

Asn Asp Trp Phe Xaa Leu
1 5

(2) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: bicyclic

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
(B) LOCATION: 5
(D) OTHER INFORMATION: Xaa is Dap, i.e. diamino propionic

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
(B) LOCATION: 1
(D) OTHER INFORMATION: Ser is Ser(β -L-arabinofuranosyl)

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
(B) LOCATION: 1 and 6
(D) OTHER INFORMATION: Ser and Leu are bound together to form a first cyclo

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
(B) LOCATION: 2 and 5
(D) OTHER INFORMATION: Asp and Dap are bound together to form a second cycle

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

Ser Asp Trp Phe Xaa Leu
1 5

(2) INFORMATION FOR SEQ ID NO: 10:

(1) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: bicyclic

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 5

(D) OTHER INFORMATION: Xaa is Dap, i.e. diamino propionic

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 1

(D) OTHER INFORMATION: Asn is Asn(β -D-mannopyranosyl)

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 1 and 6

(D) OTHER INFORMATION: Asn and Leu are bound together to form a first cyclo

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 2 and 5

(D) OTHER INFORMATION: Asp and Dap are bound together to form a second cyclo

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

Asn	Asp	Trp	Phe	Xaa	Leu
1				5	

(2) INFORMATION FOR SEQ ID NO: 11:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 6 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: bicyclic

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 5

(D) OTHER INFORMATION: Xaa is Dap, i.e. diamino propionic

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 1

(D) OTHER INFORMATION: Ser is Ser(β -D-mannopyranosyl)

(ix) **FEATURE:**

- (A) NAME/KEY: Modified-site
(B) LOCATION: 1 and 6
(D) OTHER INFORMATION: Ser and Leu are bound together to form a first cyclo

(1x) FEATURE:

- (A) NAME/KEY: Modified-site
(B) LOCATION: 2 and 5
(D) OTHER INFORMATION: Asp and Dap are bound together to form a second cyclo

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

Ser Asp Trp Phe Xaa Leu
1 5

(2) INFORMATION FOR SEQ ID NO: 12:

(1) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: bicyclic

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- ```
(A) NAME/KEY: Modified-site
(B) LOCATION: 5
(D) OTHER INFORMATION: Xaa is Dap, i.e. diamino propionic
```

(ix) FEATURE:

- (A) NAME/KEY: Modified-site  
(B) LOCATION: 1  
(D) OTHER INFORMATION: Asn is Asn( $\beta$ -D-galactopyranosyl)

( 1x ) FEATURE:

- (A) NAME/KEY: Modified-site  
(B) LOCATION: 1 and 6  
(D) OTHER INFORMATION: Asn and Leu are bound together to form a first cycle

(1x) FEATURE:

- (A) NAME/KEY: Modified-site  
(B) LOCATION: 2 and 5  
(D) OTHER INFORMATION: Asp and Dap are bound together to form a second cycle



## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

Asn Asp Trp Phe Xaa Leu  
1 5

## (2) INFORMATION FOR SEQ ID NO: 13:

- (1) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 6 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: bicyclic

(ii) MOLECULE TYPE: peptide

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site  
(B) LOCATION: 5  
(D) OTHER INFORMATION: Xaa is Dap, i.e. diamino propionic

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site  
(B) LOCATION: 1  
(D) OTHER INFORMATION: Ser is Ser( $\beta$ -D-galactopyranosyl)

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site  
(B) LOCATION: 1 and 6  
(D) OTHER INFORMATION: Ser and Leu are bound together to form a first cyclo

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site  
(B) LOCATION: 2 and 5  
(D) OTHER INFORMATION: Asp and Dap are bound together to form a second cyclo

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

Ser Asp Trp Phe Xaa Leu  
1 5

(2) INFORMATION FOR SEQ ID NO: 14:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 6 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: bicyclic

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site  
(B) LOCATION: 5  
(D) OTHER INFORMATION: Xaa is Dap, i.e. diamino propionic

(ix) FEATURE:

- (A) NAME/KEY: Modified-site  
(B) LOCATION: 1  
(D) OTHER INFORMATION: Asn is Asn( $\beta$ -D-glucuronopyranosyl)

(ix) FEATURE:

- (A) NAME/KEY: Modified-site  
(B) LOCATION: 1 and 6  
(D) OTHER INFORMATION: Asn and Leu are bound together to form a first cyclo

(ix) **FEATURE:**

- (A) NAME/KEY: Modified-site  
(B) LOCATION: 2 and 5  
(D) OTHER INFORMATION: Asp and Dap are bound together to form a second cyclo

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

Asn Asp Trp Phe Xaa Leu  
1 5

(2) INFORMATION FOR SEQ ID NO: 15:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 6 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: bicyclic

(ii) MOLECULE TYPE: peptide

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 5
- (D) OTHER INFORMATION: Xaa is Dap, i.e. diamino propionic

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1
- (D) OTHER INFORMATION: Ser is Ser( $\beta$ -D-glucuronopyranosyl)

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1 and 6
- (D) OTHER INFORMATION: Ser and Leu are bound together to form a first cyclo

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 2 and 5
- (D) OTHER INFORMATION: Asp and Dap are bound together to form a second cyclo

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

Ser Asp Trp Phe Xaa Leu  
1 5

## (2) INFORMATION FOR SEQ ID NO: 16:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: bicyclic

## (ii) MOLECULE TYPE: peptide

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 5
- (D) OTHER INFORMATION: Xaa is Dap, i.e. diamino propionic

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1
- (D) OTHER INFORMATION: Asn is Asn(1-deoxy-sorbitol-1-yl)

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1 and 6
- (D) OTHER INFORMATION: Asn and Leu are bound together to form a first cyclo

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 2 and 5
- (D) OTHER INFORMATION: Asp and Dap are bound together to form a second cyclo

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

Asn Asp Trp Phe Xaa Leu  
1                    5

## (2) INFORMATION FOR SEQ ID NO: 17:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: bicyclic

## (ii) MOLECULE TYPE: peptide

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 5
- (D) OTHER INFORMATION: Xaa is Dap, i.e. diamino propionic

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1
- (D) OTHER INFORMATION: Asn is Asn[4-O-( $\alpha$ -D-Glc)- $\beta$ -D-Glc], wherein Glc is glucopyranosyl

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1 and 6
- (D) OTHER INFORMATION: Asn and Leu are bound together to form a first cyclo

## (ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 2 and 5

(D) OTHER INFORMATION: Asp and Dap are bound together to form a second cyclo

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

Asn Asp Trp Phe Xaa Leu  
1 5

## (2) INFORMATION FOR SEQ ID NO: 18:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 6 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: bicyclic

## (ii) MOLECULE TYPE: peptide

## (ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 5

(D) OTHER INFORMATION: Xaa is Dap, i.e. diamino propionic

## (ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 1

(D) OTHER INFORMATION: Asn is Asn[4-O-( $\beta$ -D-galactopyranosyl  
- $\beta$ -D-Glc]

## (ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 1 and 6

(D) OTHER INFORMATION: Asn and Leu are bound together to form a first cyclo

## (ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 2 and 5

(D) OTHER INFORMATION: Asp and Dap are bound together to form a second cyclo

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

Asn Asp Trp Phe Xaa Leu  
1 5

## (2) INFORMATION FOR SEQ ID NO: 19:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: bicyclic

## (ii) MOLECULE TYPE: peptide

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 5
- (D) OTHER INFORMATION: Xaa is Dap, i.e. diamino propionic

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1
- (D) OTHER INFORMATION: Asn is Asn[O- $\alpha$ -D-Glc-(1-4)-O- $\alpha$ -D-Glc-(1-4)- $\alpha$ -D-Glc], wherein Glc is glucopyranosyl

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1 and 6
- (D) OTHER INFORMATION: Asn and Leu are bound together to form a first cyclo

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 2 and 5
- (D) OTHER INFORMATION: Asp and Dap are bound together to form a second cyclo

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

Asn Asp Trp Phe Xaa Leu  
1                    5

## (2) INFORMATION FOR SEQ ID NO: 20:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: bicyclic

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 5

(D) OTHER INFORMATION: Xaa is Dap, i.e. diamino propionic

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 1

(D) OTHER INFORMATION: Asn is Asn(D-2-deoxy-glucopyranos-2-yl)

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 1 and 6

(D) OTHER INFORMATION: Asn and Leu are bound together to form a first cyclo

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 2 and 5

(D) OTHER INFORMATION: Asp and Dap are bound together to form a second cyclo

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

Asn Asp Trp Phe Xaa Leu  
1 5

(2) INFORMATION FOR SEQ ID NO: 21:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 6 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: bicyclic

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 1

(D) OTHER INFORMATION: Xaa is Dap[D(-)-quinyll]

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 5

(D) OTHER INFORMATION: Xaa is Dap, i.e. diamino propionic

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1 and 6
- (D) OTHER INFORMATION: Dap[D(-)-quinyl] and Leu are bound together to form a first cyclo

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 2 and 5
- (D) OTHER INFORMATION: Asp and Dap are bound together to form a second cyclo

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

Xaa Asp Trp Phe Xaa Leu  
1 5

## (2) INFORMATION FOR SEQ ID NO: 22:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: bicyclic

## (ii) MOLECULE TYPE: peptide

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1
- (D) OTHER INFORMATION: Xaa is Dap[D-gluconyl]

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 5
- (D) OTHER INFORMATION: Xaa is Dap, i.e. diamino propionic

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1 and 6
- (D) OTHER INFORMATION: Dap[D-gluconyl] and Leu are bound together to form a first cyclo

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 2 and 5
- (D) OTHER INFORMATION: Asp and Dap are bound together to form a second cyclo



(x1) SEQUENCE DESCRIPTION: SEQ ID NO: 22:

Xaa Asp Trp Phe Xaa Leu  
1 5

(2) INFORMATION FOR SEQ ID NO: 23:

(1) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: bicyclic

(11) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1
- (D) OTHER INFORMATION: Xaa is Dap[D-glucuryl]

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 5
- (D) OTHER INFORMATION: Xaa is Dap, i.e. diamino propionic

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1 and 6
- (D) OTHER INFORMATION: Dap[D-glucuryl] and Leu are bound together to form a first cyclo

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 2 and 5
- (D) OTHER INFORMATION: Asp and Dap are bound together to form a second cyclo

(x1) SEQUENCE DESCRIPTION: SEQ ID NO: 23:

Xaa Asp Trp Phe Xaa Leu  
1 5

(2) INFORMATION FOR SEQ ID NO: 24:

- (i) SEQUENCE CHARACTERISTICS:  
  (A) LENGTH: 6 amino acids  
  (B) TYPE: amino acid  
  (C) STRANDEDNESS: single  
  (D) TOPOLOGY: bicyclic
- (ii) MOLECULE TYPE: peptide
- (ix) FEATURE:  
  (A) NAME/KEY: Modified-site  
  (B) LOCATION: 1  
  (D) OTHER INFORMATION: Xaa is Dap(sulfo-benzoyl)
- (ix) FEATURE:  
  (A) NAME/KEY: Modified-site  
  (B) LOCATION: 5  
  (D) OTHER INFORMATION: Xaa is Dap, i.e. diamino propionic
- (ix) FEATURE:  
  (A) NAME/KEY: Modified-site  
  (B) LOCATION: 1 and 6  
  (D) OTHER INFORMATION: Dap(sulfo-benzoyl) and Leu are bound together to form a first cyclo
- (ix) FEATURE:  
  (A) NAME/KEY: Modified-site  
  (B) LOCATION: 2 and 5  
  (D) OTHER INFORMATION: Asp and Dap are bound together to form a second cyclo
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:
- |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|
| Xaa | Asp | Trp | Phe | Xaa | Leu |
| 1   |     |     |     | 5   |     |

(2) INFORMATION FOR SEQ ID NO: 25:

- (i) SEQUENCE CHARACTERISTICS:  
  (A) LENGTH: 6 amino acids  
  (B) TYPE: amino acid  
  (C) STRANDEDNESS: single  
  (D) TOPOLOGY: bicyclic
- (ii) MOLECULE TYPE: peptide

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1
- (D) OTHER INFORMATION: Asn is Asn(4-sulfo-phenyl)

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 5
- (D) OTHER INFORMATION: Xaa is Dap, i.e. diamino propionic

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1 and 6
- (D) OTHER INFORMATION: Asn and Leu are bound together to form a first cyclo

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 2 and 5
- (D) OTHER INFORMATION: Asp and Dap are bound together to form a second cyclo

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:

Asn Asp Trp Phe Xaa Leu  
1 5

## (2) INFORMATION FOR SEQ ID NO: 26:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: bicyclic

## (ii) MOLECULE TYPE: peptide

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1
- (D) OTHER INFORMATION: Asn is Asn( $\beta$ -L-Glc), wherein Glc is glucopyranosyl

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 5
- (D) OTHER INFORMATION: Xaa is Dap, i.e. diamino propionic

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1 and 6
- (D) OTHER INFORMATION: Asn and Leu are bound together to form a first cyclo

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 2 and 5
- (D) OTHER INFORMATION: Asp and Dap are bound together to form a second cyclo

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:

Asn Asp Trp Phe Xaa Leu  
1 5

## (2) INFORMATION FOR SEQ ID NO: 27:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: bicyclic

## (ii) MOLECULE TYPE: peptide

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1
- (D) OTHER INFORMATION: Asn is Asn( $\beta$ -D-2-deoxy-glucopyranos-2-yl)

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 5
- (D) OTHER INFORMATION: Xaa is Dap, i.e. diamino propionic

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1 and 6
- (D) OTHER INFORMATION: Asn and Leu are bound together to form a first cyclo

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 2 and 5
- (D) OTHER INFORMATION: Asp and Dap are bound together to form a second cyclo

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:

Asn Asp Trp Phe Xaa Leu  
1                    5

(2) INFORMATION FOR SEQ ID NO: 28:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: bicyclic

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1
- (D) OTHER INFORMATION: Asn is Asn(D-2-deoxy-mannopyranos-2-yl)

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 5
- (D) OTHER INFORMATION: Xaa is Dap, i.e. diamino propionic

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1 and 6
- (D) OTHER INFORMATION: Asn and Leu are bound together to form a first cyclo

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 2 and 5
- (D) OTHER INFORMATION: Asp and Dap are bound together to form a second cyclo

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:

Asn Asp Trp Phe Xaa Leu  
1                    5

(2) INFORMATION FOR SEQ ID NO: 29:

(1) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: bicyclic

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site  
(B) LOCATION: 1  
(D) OTHER INFORMATION: Asn is Asn(D-2-deoxy-galactopyranos

2-y1

(ix) FEATURE:

- (A) NAME/KEY: Modified-site  
(B) LOCATION: 5  
(D) OTHER INFORMATION: Xaa is Dap, i.e. diamino propionic

( 1x ) FEATURE:

- (A) NAME/KEY: Modified-site  
(B) LOCATION: 1 and 6  
(D) OTHER INFORMATION: Asn and Leu are bound together to form a first cyclo

**(1x) FEATURE:**

- (A) NAME/KEY: Modified-site  
(B) LOCATION: 2 and 5  
(D) OTHER INFORMATION: Asp and Dap are bound together to form a second cyclo

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29:

Asn Asp Trp Phe Xaa Leu  
1 5

(2) INFORMATION FOR SEQ ID NO: 30:

(1) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: bicyclic

(11) MOLECULE TYPE: peptide

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1
- (D) OTHER INFORMATION: Asn is Asn( $\beta$ -D-xylopyranosyl)

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 5
- (D) OTHER INFORMATION: Xaa is Dap, i.e. diamino propionic

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1 and 6
- (D) OTHER INFORMATION: Asn and Leu are bound together to form a first cyclo

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 2 and 5
- (D) OTHER INFORMATION: Asp and Dap are bound together to form a second cyclo

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30:

Asn Asp Trp Phe Xaa Leu  
1 5

## (2) INFORMATION FOR SEQ ID NO: 31:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: bicyclic

## (ii) MOLECULE TYPE: peptide

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1
- (D) OTHER INFORMATION: Asn is Asn(3-sulfo-propionyl)

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 5
- (D) OTHER INFORMATION: Xaa is Dap, i.e. diamino propionic

(ix) **FEATURE:**

- (A) NAME/KEY: Modified-site  
(B) LOCATION: 1 and 6  
(D) OTHER INFORMATION: Asn and Leu are bound together to form a first cyclo

( 1x ) FEATURE:

- (A) NAME/KEY: Modified-site  
(B) LOCATION: 2 and 5  
(D) OTHER INFORMATION: Asp and Dap are bound together to form a second cyclo

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31:

Asn Asp Trp Phe Xaa Leu  
1 5

(2) INFORMATION FOR SEQ ID NO: 32:

(1) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: bicyclic

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site  
(B) LOCATION: 1  
(D) OTHER INFORMATION: Xaa is Dap(Lysyl)

(ix) FEATURE:

- (A) NAME/KEY: Modified-site  
(B) LOCATION: 5  
(D) OTHER INFORMATION: Xaa is Dap, i.e. diamino propionic

( 1x ) FEATURE:

- (A) NAME/KEY: Modified-site  
(B) LOCATION: 1 and 6  
(D) OTHER INFORMATION: Dap(Lysyl) and Leu are bound together to form a first cyclo

( 1x ) FEATURE:

- (A) NAME/KEY: Modified-site  
(B) LOCATION: 2 and 5  
(D) OTHER INFORMATION: Asp and Dap are bound together to form a second cyclo



## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32:

Xaa Asp Trp Phe Xaa Leu  
1 5

## (2) INFORMATION FOR SEQ ID NO: 33:

## (1) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: bicyclic

(1i) MOLECULE TYPE: peptide

## (1x) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1
- (D) OTHER INFORMATION: Xaa is Dap(Arginyl)

## (1x) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 5
- (D) OTHER INFORMATION: Xaa is Dap, i.e. diamino propionic

## (1x) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1 and 6
- (D) OTHER INFORMATION: Dap(Arginyl) and Leu are bound together to form a first cyclo

## (1x) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 2 and 5
- (D) OTHER INFORMATION: Asp and Dap are bound together to form a second cyclo

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33:

Xaa Asp Trp Phe Xaa Leu  
1 5

## (2) INFORMATION FOR SEQ ID NO: 34:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: bicyclic

(ii) MOLECULE TYPE: peptide

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1
- (D) OTHER INFORMATION: Xaa is Dap(4-O- $\beta$ -D-galactopyranosyl)

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 5
- (D) OTHER INFORMATION: Xaa is Dap, i.e. diamino propionic

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1 and 6
- (D) OTHER INFORMATION: Dap(4-O- $\beta$ -D-galactopyranosyl) and Le  
are bound together to form a first cycl

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 2 and 5
- (D) OTHER INFORMATION: Asp and Dap are bound together to  
form a second cyclo

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34:

Xaa Asp Trp Phe Xaa Leu  
1 5

## (2) INFORMATION FOR SEQ ID NO: 35:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: bicyclic

(ii) MOLECULE TYPE: peptide

## (ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 1

(D) OTHER INFORMATION: Asn is Asn(2-deoxy-2-trifluoro-acetoamido- $\beta$ -D-Glc, wherein Glc is glucopyranosyl

## (ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 5

(D) OTHER INFORMATION: Xaa is Dap, i.e. diamino propionic

## (ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 1 and 6

(D) OTHER INFORMATION: Asn and Leu are bound together to form a first cyclo

## (ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 2 and 5


(D) OTHER INFORMATION: Asp and Dap are bound together to form a second cyclo

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35:

Xaa Asp Trp Phe Xaa Leu  
1 5

## CLAIMS

1. Bicycl compounds of general Formula



- wherein  $X_1$ ,  $X_2$ ,  $X_3$ ,  $X_4$ ,  $X_5$  and  $X_6$ , same or different from one another, represent a  $-NR'CO-$  or a  $-CONR'-$  group, where  $R'$  is H or  $C_{1-3}$  alkyl;  $Y$  represents a group selected from  $-NRCO-$ ,  $-CONR-$  or  $-SS-$  wherein  $R$  is H or  $C_{1-3}$  alkyl; at least one of  $R_1$ ,  $R_2$ ,  $R_3$  and  $R_4$  groups, same or different from one another, is hydrophilic and the remaining groups are hydrophobic;  $m$  and  $n$ , same or different from one another, are each an integer number from 1 to 4.
2. Compounds as claimed in claim 1, wherein the hydrophobic groups can be separately selected from the following:
- groups corresponding to  $C_nH_{2n+1}$  wherein  $n = 0, 1-4$ ;
  - linear or branched-alkyl groups corresponding to  $C_nH_{2n}-U-W$  wherein  $n = 1-4$ ;  $U = O, COO, CONH, S$  and  $W = \text{alkyl-, aryl- or alkylaryl-group}$  containing from 1 to 15 C atoms;
  - $(CH_2)_n-C_6H_3-A-B$  wherein  $n = 0, 1-3$ ;  $A$  and  $B$ , placed in any of the ortho, meta or para positions, same or different from one another, represent H, halogen, OR, NHR,  $NR_2$ ,  $CH_3$ , SR where  $R$  is an alkyl-, aryl- or alkylaryl-group with less than 10 C atoms;

- 11 d)  $(\text{CH}_2)_n\text{-C}_6\text{H}_{10}\text{R}'$ , wherein  $n = 0, 1-3$  and  $\text{R}' = \text{H}, \text{C}_{1-3}$  alkyl
- 12 e)  $(\text{CH}_2)_n\text{-heterocycle}$ , wherein  $n = 0, 1-3$  and by the term heterocyclic
- 13 imidazolyl-2-yl, indolyl-3-yl, furanyl-3-yl, piridyl-3-yl, imidazolyl-
- 14 3-yl are meant;
- 15 f) a  $-(\text{CH}_2)_s\text{-}$  group wherein  $s = 3, 4$ , eventually OH-substituted or
- 16 condensed with an aromatic group, which cyclizes with one of the two
- 17 adjacent  $\text{X}_{1-6}$  groups in order to produce the side chain of proline,
- 18 hydroxyproline, octahydroindol-2-carboxylic acid, tetrahydroiso-
- 19 quinolinic acid;
- 20 g) the side chain of a natural hydrophobic amino acid;
- 21 h) the side chain of a natural hydrophilic amino acid, suitably
- 22 substituted in order to render it hydrophobic;
- 23 i) the side chain of non-natural hydrophobic amino acids selected from
- 24 the group consisting of: norleucine, norvaline, alloisoleucine,
- 25 cyclohexylglycine (Chg),  $\alpha$ -amino-n-butyric-acid (Aba),
- 26 cyclohexylalanine (Cha), aminophenylbutyric acid (Pba), mono- and di-
- 27 substituted phenylalanines in ortho, meta and para positions of the
- 28 benzene ring with one or more of the following groups:  $\text{C}_{1-10}$  alkyl,
- 29  $\text{C}_{1-10}$  alkoxy, halogen,  $\beta$ -2-thienylalanine,  $\beta$ -3-thienylalanine,  $\beta$ -2-
- 30 furanylalanine,  $\beta$ -3-furanylalanine,  $\beta$ -2-piridylalanine,  $\beta$ -3-
- 31 piridylalanine,  $\beta$ -4-piridylalanine,  $\beta$ -(1-naphtyl)alanine,  $\beta$ -(2-
- 32 naphtyl)alanine, O-alkylated serine-threonine-tyrosine-derivatives,
- 33 S-alkyl cysteine, S-alkyl homocysteine, N-alkyl lysine, N-alkyl
- 34 ornithine, N-alkyl 2,3 diaminopropionic acid.
- 1 3. Compounds as claimed in claim 2 wherein the side chain of a
- 2 hydrophobic amino acid according to paragraph g) is the side chain of
- 3 an amino acid selected from the group consisting of: glycine, alanine,

4 valine, leucine, isoleucine, methionine, phenylalanine, tyrosine,  
5 tryptophan, proline, histidine, asparagine, glutamine.

1 4. Compounds as claimed in claim 2, wherein the side chain of an  
2 hydrophilic amino acid suitably substituted according to paragraph (h)  
3 is the side chain of an amino acid selected from the group consisting  
4 of: serine, threonine, cysteine, aspartic acid, glutamic acid, t-  
5 carboxyglutamic acid, arginine, ornithine, lysine.

1 5. Compounds according to Claim 2 wherein the hydrophilic groups are  
2 chosen in the group L-Q wherein L is a chemical bond or a linear or  
3 branched C<sub>1-6</sub> alkyl-group and Q is chosen in the group consisting of:  
4 i) hydroxyl, amine, guanidine, carboxyl, sulfate, phosphonate,  
5 phosphate;  
6 ii) linear, branched or cyclic C<sub>1-6</sub> alkyl chain containing one or more  
7 hydroxyl, amine, guanidine, carboxyl, sulfate, phosphate;  
8 iii) an aromatic group mono-, di- or tri-substituted ortho-, meta-,  
9 para-position with hydroxyl, amino, guanidine, carboxyl, sulfate,  
10 phosphate;  
11 iv) a group M, OM, CONHM, NHCOM wherein M is an hydrophilic group  
12 v) an hydrophilic group according to points i)-iv) protected with  
13 groups which are biologically hydrolyzed reforming an hydrophilic  
14 group.

1 6. Compounds according to Claim 5 wherein the group M is chosen in the  
2 group consisting of:  
3 i) eventually substituted mono-, di-, tri-glycosidic residues;  
4 ii) linear, branched or cyclic C<sub>1-6</sub> alkyl-chains, containing one or  
5 more groups hydroxyl, amine, guanidine, carboxyl, sulfate,  
6 phosphonate, phosphate.

1 7. Compounds of Formula (I) as claimed in claim 6, wherein the  
2 glycosidic residues are selected from the group consisting of:  
3 hexoses or pentoses of D or L series in  $\alpha$  or  $\beta$  configuration, selected  
4 from the group wherein: all C atoms bear a free or protected  
5 hydroxylic group; one or more hydroxyls are substituted by: hydrogen;  
6 an amino or acylamino group; C<sub>6</sub> of hexoses and C<sub>5</sub> of pentoses are  
7 part of a carboxylic group; and wherein the eventually present 2 or 3  
8 glycosidic units are linked by a glycosidic bond of  $\alpha$  or  $\beta$   
9 configuration.

1 8. Compounds of general Formula (I) according to claim 7 selected from  
2 the group consisting of: D or L ribose, D or L arabinose, D or L  
3 xylose, D or L lyxose, D or L allose, D or L altrose, D or L glucose,  
4 D or L mannose, D or L gulose, D or L idose, D or L galactose, D or L  
5 talose, D or L allulose, D or L fructose, D or L sorbose, D or L  
6 tagatose; 5-deoxy-D or L-arabinose, 2-deoxy-D or L-glucose, 2-deoxy-D  
7 or L-galactose, 2-deoxy-D or L-arabinose, 2-deoxy-D or L-ribose, D or  
8 L fucose, D or L ramnose; D-glucosamine, D-mannosamine, D-  
9 galactosamine, daunosamine, acosamine and N-acylate derivates thereof  
10 with lower fat acids, i.e. containing a N-formylic, acetylic,  
11 propionilic, butyric residue; glucuronic acid, galacturonic acid;  
12 cellobiose, lactose, maltose, D-lactosamine, cellotriose, maltotriose;  
13 tris(hydroxymethyl)methyl, D or L arabitol, D or L erythrol, D or L  
14 perseitol, D or L ribitol, D or L sorbitol, D or L xylitol; or those  
15 from the residue of tartaric acid, glucaric acid, gluconic acid,  
16 bycin, quinic acid, mucic acid, glucosaminic acid.

1 9. Compounds of general Formula (I) according to claim 1, wherein if  
2 on or both R<sub>1</sub> and R<sub>4</sub> groups are hydrophilic, both R<sub>2</sub> and R<sub>3</sub> groups

3 are hydrophobic or viceversa.

1 10. Compounds as claimed in claim 1, as hereinafter indicated:

2 i) cyclo([Asn( $\beta$ -D-Glc)-Asp-Trp-Phe-Dap-Leu]cyclo(2 $\beta$ -5 $\beta$ )) (SEQ ID No. 1)

3 ii) cyclo([Ser( $\beta$ -D-Glc)-Asp-Trp-Phe-Dap-Leu]cyclo(2 $\beta$ -5 $\beta$ )) (SEQ ID No.

4 2)

5 iii) cyclo ([Asn ( $\beta$ -D-2-deoxy-2-amino-Glc)-Asp-Trp-Phe-Dap-Leu]

6 cyclo (2 $\beta$ -5 $\beta$ )) (SEQ ID No. 3)

7 iv) cyclo ( [Asn( $\beta$ -D-2-deoxy-2-acetamido-Glc)-Asp-Trp-Phe-Dap-

8 Leu]cyclo(2 $\beta$ -5 $\beta$ )) (SEQ ID No. 4)

9 v) cyclo([Nle-Asp-Trp-Phe-Dap-Asn( $\beta$ -D-2-deoxy-2-acetamido-Glc)]

10 cyclo(2 $\beta$ -5 $\beta$ )) (SEQ ID 5)

11 vi) cyclo ([Asn( $\beta$ -D-ribofuranosyl)-Asp-Trp-Phe-Dap-Leu]cyclo

12 (2 $\beta$ -5 $\beta$ )) (SEQ ID 6)

13 vii) cyclo ( [ Ser( $\beta$ -D-ribofuranosyl)-Asp-Trp-Phe-Dap-Leu] cyclo

14 (2 $\beta$ -5 $\beta$ )) (SEQ ID No. 7)

15 viii) cyclo([Asn( $\beta$ -L-arabinofuranosyl)-Asp-Trp-Phe-Dap-Leu]cyclo

16 (2 $\beta$ -5 $\beta$ )) (SEQ ID No. 8)

17 ix) cyclo([Ser( $\beta$ -L-arabinofuranosyl)-Asp-Trp-Phe-Dap-Leu]cyclo

18 (2 $\beta$ -5 $\beta$ )) (SEQ ID No. 9)

19 x) cyclo([Asn( $\beta$ -D-mannopyranosyl)-Asp-Trp-Phe-Dap-Leu] cyclo(2 $\beta$ -5 $\beta$ ))

20 (SEQ ID No. 10)

21 xi) cyclo([Ser( $\beta$ -D-mannopyranosyl)-Asp-Trp-Phe-Dap-Leu] cyclo(2 $\beta$ -5 $\beta$ ))

22 (SEQ ID No. 11)

23 xii) cyclo([Asn( $\beta$ -D-galactopyranosyl)-Asp-Trp-Phe-Dap-Leu]cyclo (2 $\beta$ -

24 5 $\beta$ )) (SEQ ID No. 12)

25 xiii) cyclo([Ser( $\beta$ -D-galactopyranosyl)-Asp-Trp-Phe-Dap-Leu]cyclo (2 $\beta$ -

26 5 $\beta$ )) (SEQ ID No. 13)



- 27 xiv) cyclo ([Asn( $\beta$ -D-glucuronopyranosyl)-Asp-Trp-Phe-Dap-  
28 Leu]cyclo(2 $\beta$ -5 $\beta$ )) (SEQ ID No. 14)  
29 xv) cyclo ([Ser( $\beta$ -D-glucuronopyranosyl)-Asp-Trp-Phe-Dap-Leu]  
30 cyclo(2 $\beta$ -5 $\beta$ )) (SEQ ID No. 15)  
31 xvi) cyclo ([Asn(1-deoxy-sorbitol-1-yl)-Asp-Trp-Phe-Dap-Leu]cyclo  
32 (2 $\beta$ -5 $\beta$ )) (SEQ ID No. 16)  
33 xvii) cyclo ([Asn [(4-O-( $\alpha$ -D-Glc)- $\beta$ -D-Glc)]-Asp-Trp-Phe-Dap-  
34 Leu]cyclo(2 $\beta$ -5 $\beta$ )) (SEQ ID No. 17)  
35 xviii) cyclo ([Asn[(4-O-( $\alpha$ -D-galactopyranosyl)- $\beta$ -D-Glc)]-Asp-Trp-Phe-  
36 Dap-Leu]cyclo(2 $\beta$ -5 $\beta$ )) (SEQ ID No. 18)  
37 xix) cyclo ([Asn [O- $\alpha$ -D-Glc-(1-4)-O- $\alpha$ -D-Glc-(1-4)- $\alpha$ -D-Glc]-Asp-Trp-  
38 Phe-Dap-Leu] cyclo(2 $\beta$ -5 $\beta$ )) (SEQ ID No. 19)  
39 xx) cyclo ([Asn(D-2-deoxy-glucopyranos-2-yl)-Asp-Trp-Phe-Dap-  
40 Leu]cyclo(2 $\beta$ -5 $\beta$ )) (SEQ ID No. 20)  
41 xxi) cyclo ([Dap[D(-)-quinyl]-Asp-Trp-Phe-Dap-Leu]cyclo(2 $\beta$ -5 $\beta$ )) (SEQ  
42 ID No. 21)  
43 xxii) cyclo ([Dap[D-gluconyl]-Asp-Trp-Phe-Dap-Leu] cyclo (2 $\beta$ -5 $\beta$ )) (SEQ  
44 ID No. 22)  
45 xxiii) cyclo ([Dap[D-glucuryl]-Asp-Trp-Phe-Dap-Leu]cyclo(2 $\beta$ -5 $\beta$ )) (SEQ  
46 ID No. 23)  
47 xxiv) cyclo([Dap(2-sulfo-benzoyl)-Asp-Trp-Phe-Dap-Leu]cyclo(2 $\beta$ -5 $\beta$ ))  
48 (SEQ ID No. 24)  
49 xxv) cyclo ([Asn(4-sulfo-phenyl)-Asp-Trp-Phe-Dap-Leu]cyclo(2 $\beta$ -5 $\beta$ ))  
50 (SEQ ID No. 25)  
51 xxvi) cyclo ([Asn( $\beta$ -L-Glc)-Asp-Trp-Phe-Dap-Leu]cyclo(2 $\beta$ -5 $\beta$ )) (SEQ ID  
52 No. 26)  
53 xxvii) cyclo ([Asn( $\beta$ -D-2-de xy-glucopyran s-2-yl)-Asp-Trp-Phe-Dap-

- 54 Leu]cyclo(2 $\beta$ -5 $\beta$ )) (SEQ ID No. 27)
- 55 xxviii) cyclo ([Asn( $\beta$ -D-2-deoxy-mannopyranos-2-yl)-Asp-Trp-Phe-Dap-  
56 Leu]cyclo(2 $\beta$ -5 $\beta$ )) (SEQ ID No. 28)
- 57 xxix) cyclo ([Asn(D-2-deoxy-galactopyranos-2-yl)-Asp-Trp-Phe-Dap-  
58 Leu]cyclo(2 $\beta$ -5 $\beta$ )) (SEQ ID No. 29)
- 59 xxx) cyclo ([Asn( $\beta$ -D-xylopyranosyl)-Asp-Trp-Phe-Dap-Leu]cyclo(2 $\beta$ -5 $\beta$ ))  
60 (SEQ ID No. 30)
- 61 xxxi) cyclo ([Asn(3-sulfo-propionyl)-Asp-Trp-Phe-Dap-Leu]cyclo (2 $\beta$ -  
62 5 $\beta$ )) (SEQ ID No. 31)
- 63 xxxii) cyclo ([Dap(Lysyl)-Asp-Trp-Phe-Dap-Leu]cyclo(2 $\beta$ -5 $\beta$ )) (SEQ ID  
64 No. 32)
- 65 xxxiii) cyclo ([Dap(Arginyl)-Asp-Trp-Phe-Dap-Leu]cyclo(2 $\beta$ -5 $\beta$ )) (SEQ ID  
66 No. 33)
- 67 xxxiv) cyclo ([Dap(4-O- $\beta$ -D-galactopyranosyl)-Asp-Trp-Phe-Dap-Leu]  
68 cyclo(2 $\beta$ -5 $\beta$ )) (SEQ ID No. 34)
- 69 xxxv) cyclo ([Asn(2-deoxy-2-trifluoroacetamido- $\beta$ -D-Glc)-Asp-Trp-Phe-  
70 Dap-Leu]cyclo(2 $\beta$ -5 $\beta$ )) (SEQ ID No. 35).

1 11. Pharmaceutical compositions containing as active principle  
2 compounds of general Formula (I) as claimed in claim 1. combined to  
3 suitable carriers.

1 12. Pharmaceutical compositions according to claim 11 for use as  
2 tachykinins antagonists.

1 13. Pharmaceutical compositions as claimed in claim 12 for treatment  
2 of arthrytis, asthma, inflammations, tumoral growth, gastrointestinal  
3 hyp rmotility, Huntingt n's diseas , neuritis, n uralgia, hemicrania,  
4 hypertension, urinary incontinence, urticaria, symptoms from carcin id  
5 syndrome, flu and cold.

1 14. Methods for treatment of arthrytis, asthma, inflammations, tumoral  
2 growth, gastrointestinal hypermotility, Huntington's desease,  
3 neuritis, neuralgia, hemicrania, hypertension, urinary incontinence,  
4 urticaria, symptoms from carcinoid syndrome, flu and cold, all  
5 conditions in which doses comprised between 0.1 and 10 mg/Kg of body  
6 weight of active principle consisting of the products of Formula (I),  
7 according to claim 1, are administered to the patient.

## INTERNATIONAL SEARCH REPORT

In International Application No

PC 96/01028

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07K7/22 C07K7/56 C07K7/64 C07K9/00 A61K38/12

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages                                                                                                                                                                 | Relevant to claim No. |
|------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| Y          | WO,A,93 21227 (MENARINI ET AL.) 28 October 1993<br>cited in the application<br>see the whole document<br>---                                                                                                                                       | 1-9,<br>11-14         |
| Y          | INTERNATIONAL JOURNAL OF PEPTIDE AND<br>PROTEIN RESEARCH,<br>vol. 44, no. 2, August 1994, COPENHAGEN<br>DK,<br>pages 105-111, XP000456585<br>G HÖLZEMANN ET AL.: "Cyclic hexapeptide<br>NK-2 antagonists"<br>see the whole document<br>---<br>-/-- | 1-9,<br>11-14         |

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- \*&\* document member of the same patent family

Date of the actual completion of the international search

5 July 1996

Date of mailing of the international search report

25.07.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Masturzo, P

# INTERNATIONAL SEARCH REPORT

ional Application No

CT/EP 96/01028

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document, with indication, where appropriate, of the relevant passages                                                                                                                                                                                                                                                                                                                               | Relevant to claim No. |
|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| A        | <p>CHEMICAL ABSTRACTS, vol. 122, no. 5,<br/> 30 January 1995<br/> Columbus, Ohio, US;<br/> abstract no. 46372p,<br/> C A MAGGI ET AL.: "MEN 10, 627, a novel<br/> polycyclic peptide antagonist of<br/> tachykinin NK-2 receptors"<br/> page 114;<br/> XP002007657<br/> see abstract<br/> &amp; J PHARM EXP THER,<br/> vol. 271, no. 3, 1994,<br/> pages 1489-1500,</p> <p style="text-align: center;">-----</p> | 1-14                  |

# INTERNATIONAL SEARCH REPORT

International application No.

EP 96/ 01028

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claim 14 refers to a method of treatment of the human body the search was carried out and based on the alleged effects of the products.
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 96/01028

| Patent document<br>cited in search report | Publication<br>date | Patent family<br>member(s) | Publication<br>date |
|-------------------------------------------|---------------------|----------------------------|---------------------|
| WO-A-9321227                              | 28-10-93            | BG-A- 99110                | 29-09-95            |
|                                           |                     | CZ-A- 9402542              | 12-07-95            |
|                                           |                     | EP-A- 0636146              | 01-02-95            |
|                                           |                     | FI-A- 944838               | 14-10-94            |
|                                           |                     | HU-A- 70189                | 28-09-95            |
|                                           |                     | JP-T- 8500331              | 16-01-96            |
|                                           |                     | NO-A- 943861               | 13-10-94            |
|                                           |                     | SK-A- 124294               | 11-07-95            |
|                                           |                     | ZA-A- 9302644              | 22-10-93            |
| -----                                     |                     |                            |                     |

